Bogdana Suchorska1,2, Marcus Unterrainer3,4, Annamaria Biczok5,3, Marketa Sosnova5,4, Robert Forbrig6, Peter Bartenstein3,4, Jörg-Christian Tonn5,3, Nathalie Lisa Albert3,4, Friedrich-Wilhelm Kreth5,3. 1. Department of Neurosurgery, Ludwig-Maximilians University, University Hospital Munich, Marchioninistr. 15, 81377, Munich, Germany. Bogdana.Suchorska@med.uni-muenchen.de. 2. German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany. Bogdana.Suchorska@med.uni-muenchen.de. 3. German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany. 4. Department of Nuclear Medicine, Ludwig-Maximilians University, Munich, Germany. 5. Department of Neurosurgery, Ludwig-Maximilians University, University Hospital Munich, Marchioninistr. 15, 81377, Munich, Germany. 6. Department of Neuroradiology, Ludwig-Maximilians University, Munich, Germany.
Abstract
BACKGROUND: Monitoring treatment response after chemotherapy of gadolinium-(Gd)-negative gliomas is challenging as conventional MRI often indicates no radiological changes. We hypothesize that 18F-FET-PET can be used as a biomarker for response assessment in Gd-negative gliomas undergoing chemotherapy. METHODS: Sixty-one patients harboring Gd-negative WHO grade II or III glioma receiving alkylating agents (temozolomide or CCNU/procarbacine) were included. All patients underwent MRI and 18F-FET-PET before chemotherapy and 6 months later. We calculated T2-volume, 18F-FET-PET based biological tumour volume (BTV) and maximal tumour-to-brain ratio (TBRmax). Moreover, dynamic PET acquisition was performed using time-activity-curves (TACs) analysis. For MRI-based response assessment, RANO criteria for low-grade glioma were used. For 18F-FET-PET, following classification scheme was tested: responsive disease (RD) when a decrease in either BTV ≥ 25% and/or TBRmax ≥ 10% occurred, an increase in BTV ≥ 25% and/or TBRmax increase > 10% characterized progressive disease (PD), minor changes ± 25% for BTV and ± 10% for TBRmax were regarded as stable disease (SD). Post-chemotherapy survival (PCS) and time-to-treatment failure (TTF) were calculated using the Kaplan-Meier method. RESULTS: 18F-FET-PET based response has shown patients with RD to have the longest TTF time (78.5 vs 24.6 vs 24.1 months, p = 0.001), while there was no significant difference between patients with a SD and PD. A comparable pattern was observed for PCS (p < 0.001). T2-volume based assessment was not associated with outcome. CONCLUSION: 18F-FET-PET is a promising biomarker for early response assessment in Gd-negative gliomas undergoing chemotherapy. It might be helpful for a timely adjustment of potentially ineffective treatment concepts and overcomes limitations of conventional structural imaging.
BACKGROUND: Monitoring treatment response after chemotherapy of gadolinium-(Gd)-negative gliomas is challenging as conventional MRI often indicates no radiological changes. We hypothesize that 18F-FET-PET can be used as a biomarker for response assessment in Gd-negative gliomas undergoing chemotherapy. METHODS: Sixty-one patients harboring Gd-negative WHO grade II or III glioma receiving alkylating agents (temozolomide or CCNU/procarbacine) were included. All patients underwent MRI and 18F-FET-PET before chemotherapy and 6 months later. We calculated T2-volume, 18F-FET-PET based biological tumour volume (BTV) and maximal tumour-to-brain ratio (TBRmax). Moreover, dynamic PET acquisition was performed using time-activity-curves (TACs) analysis. For MRI-based response assessment, RANO criteria for low-grade glioma were used. For 18F-FET-PET, following classification scheme was tested: responsive disease (RD) when a decrease in either BTV ≥ 25% and/or TBRmax ≥ 10% occurred, an increase in BTV ≥ 25% and/or TBRmax increase > 10% characterized progressive disease (PD), minor changes ± 25% for BTV and ± 10% for TBRmax were regarded as stable disease (SD). Post-chemotherapy survival (PCS) and time-to-treatment failure (TTF) were calculated using the Kaplan-Meier method. RESULTS: 18F-FET-PET based response has shown patients with RD to have the longest TTF time (78.5 vs 24.6 vs 24.1 months, p = 0.001), while there was no significant difference between patients with a SD and PD. A comparable pattern was observed for PCS (p < 0.001). T2-volume based assessment was not associated with outcome. CONCLUSION: 18F-FET-PET is a promising biomarker for early response assessment in Gd-negative gliomas undergoing chemotherapy. It might be helpful for a timely adjustment of potentially ineffective treatment concepts and overcomes limitations of conventional structural imaging.
Authors: Nathalie L Jansen; Vera Graute; Lena Armbruster; Bogdana Suchorska; Juergen Lutz; Sabina Eigenbrod; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich Wilhelm Kreth; Christian la Fougère Journal: Eur J Nucl Med Mol Imaging Date: 2012-04-11 Impact factor: 9.236
Authors: Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn Journal: Neuro Oncol Date: 2016-04-21 Impact factor: 12.300
Authors: Michael Weller; Martin van den Bent; Jörg C Tonn; Roger Stupp; Matthias Preusser; Elizabeth Cohen-Jonathan-Moyal; Roger Henriksson; Emilie Le Rhun; Carmen Balana; Olivier Chinot; Martin Bendszus; Jaap C Reijneveld; Frederick Dhermain; Pim French; Christine Marosi; Colin Watts; Ingela Oberg; Geoffrey Pilkington; Brigitta G Baumert; Martin J B Taphoorn; Monika Hegi; Manfred Westphal; Guido Reifenberger; Riccardo Soffietti; Wolfgang Wick Journal: Lancet Oncol Date: 2017-05-05 Impact factor: 41.316
Authors: M J van den Bent; J S Wefel; D Schiff; M J B Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; A D Waldman; T Gorlia; M Chamberlain; B G Baumert; M A Vogelbaum; D R Macdonald; D A Reardon; P Y Wen; S M Chang; A H Jacobs Journal: Lancet Oncol Date: 2011-04-05 Impact factor: 41.316
Authors: M J van den Bent; J M Kros; J J Heimans; L C Pronk; C J van Groeningen; H G Krouwer; M J Taphoorn; B A Zonnenberg; C C Tijssen; A Twijnstra; C J Punt; W Boogerd Journal: Neurology Date: 1998-10 Impact factor: 9.910
Authors: Niklas Thon; Sabina Eigenbrod; Eva M Grasbon-Frodl; Michael Ruiter; Jan H Mehrkens; Simone Kreth; Jörg C Tonn; Hans A Kretzschmar; Friedrich W Kreth Journal: J Neuropathol Exp Neurol Date: 2009-11 Impact factor: 3.685
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Hiroyuki Tatekawa; Akifumi Hagiwara; Hiroyuki Uetani; Jingwen Yao; Talia C Oughourlian; Shadfar Bahri; Chencai Wang; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Whitney B Pope; Noriko Salamon; Benjamin M Ellingson Journal: J Neurooncol Date: 2020-09-14 Impact factor: 4.130
Authors: Philipp Karschnia; Nico Teske; Mario M Dorostkar; Sebastian Siller; Jonathan Weller; Joachim M Baehring; Jorg Dietrich; Louisa von Baumgarten; Jochen Herms; Joerg-Christian Tonn; Niklas Thon Journal: Sci Rep Date: 2020-11-12 Impact factor: 4.379
Authors: Kiana Y Prather; Christen M O'Neal; Alison M Westrup; Hurtis J Tullos; Kendall L Hughes; Andrew K Conner; Chad A Glenn; James D Battiste Journal: Neurooncol Adv Date: 2022-02-13
Authors: Hiroyuki Tatekawa; Hiroyuki Uetani; Akifumi Hagiwara; Shadfar Bahri; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Whitney B Pope; Noriko Salamon; Benjamin M Ellingson Journal: Ann Nucl Med Date: 2021-06-14 Impact factor: 2.668